Ocular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 3,018 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey Heier sold 3,018 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $24,747.60. Following the completion of the sale, the insider directly owned 320,350 shares in the company, valued at approximately $2,626,870. This represents a 0.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Price Performance

NASDAQ:OCUL opened at $9.15 on Friday. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44. The company has a market cap of $2.00 billion, a P/E ratio of -6.27 and a beta of 0.93. The firm’s fifty day moving average price is $8.79 and its two-hundred day moving average price is $10.23. The company has a debt-to-equity ratio of 0.12, a current ratio of 14.81 and a quick ratio of 14.73.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Monday, April 13th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.

Institutional Investors Weigh In On Ocular Therapeutix

Large investors have recently bought and sold shares of the company. Millennium Management LLC lifted its holdings in shares of Ocular Therapeutix by 3,136.1% in the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock worth $45,073,000 after acquiring an additional 3,736,560 shares during the last quarter. Alliancebernstein L.P. raised its holdings in Ocular Therapeutix by 2,003.2% in the 3rd quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after buying an additional 3,261,619 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in Ocular Therapeutix by 38.5% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after buying an additional 2,850,000 shares during the last quarter. Commodore Capital LP bought a new position in Ocular Therapeutix in the 1st quarter valued at approximately $21,810,000. Finally, Vanguard Group Inc. raised its holdings in Ocular Therapeutix by 26.3% in the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after buying an additional 2,411,953 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.